Cancer Therapeutic Procedure – Page 6

Halda Therapeutics Secures $126M to Advance ‘Hold and Kill’ Solid Tumor Drugs into Clinical Trials

11 months ago talkbio0Tagged Cancer Therapeutic Procedure, Clinical Trials, Halda, Malignant neoplasm of breast, Malignant neoplasm of prostate, RIPTAC, Series B extension financing, Solid Neoplasm

Halda Therapeutics, RIPTAC therapeutics, cancer treatment, solid tumors, prostate cancer, breast cancer, clinical trials, Series B extension financing

FDA Criticizes Bristol Myers Squibb for Misleading Efficacy Claims on Krazati Website

11 months ago talkbio0Tagged Cancer Therapeutic Procedure, Claims, Effectiveness, K-ras Oncogene, KRAZATI, Myers, Non-Small Cell Lung Carcinoma, non-small-cell lung cancer, squibb, United States Food and Drug Administration

Bristol Myers Squibb, FDA, Krazati, misleading efficacy claims, non-small-cell lung cancer, NSCLC, KRAS G12C-mutated, cancer treatment

IDRx Secures $120M for Pivotal KIT Inhibitor Study with Promising Early Data

11 months ago talkbio0Tagged Cancer Therapeutic Procedure, Clinical Research, IDRx, Inhibitor, Kit device

IDRx, KIT inhibitor, pivotal study, funding, cancer treatment, biotech

Actinium’s Radioconjugate Faces Setback as FDA Requests New Study

12 months ago talkbio0Tagged Actinium, Cancer Therapeutic Procedure, Clinical Research, Iomab-B, Radioconjugate, Regulatory Affairs, United States Food and Drug Administration

Actinium Pharmaceuticals, radioconjugate, FDA, new study, Iomab-B, regulatory affairs, biotech, cancer treatment

BioNTech and Regeneron Achieve Significant Response Rate Success in Phase 2 Trial for mRNA Cancer Immunotherapy BNT111

12 months ago talkbio0Tagged BioNTech, Cancer Therapeutic Procedure, cemiplimab, checkpoint inhibitor, melanoma, mRNA immunotherapy, mRNA-LPX technology, PDCD1 gene, Phase 2 trial, Regeneron, Tetravalent RNA-lipoplex Cancer Vaccine BNT111, uridine

BioNTech, Regeneron, mRNA immunotherapy, BNT111, Phase 2 trial, melanoma, cancer treatment, PD-1 checkpoint inhibitor, cemiplimab, FixVac platform, uridine mRNA-LPX technology

AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront

12 months ago talkbio0Tagged AstraZeneca, Cancer Therapeutic Procedure, Epidermal Growth Factor Receptor, licensing agreement, milestone payments, molecular glues, Neoplasms, Pinetree, Protein Degradation, Metabolic, protein degrader, royalties

AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment